Biodeal Pharmaceuticals Raises ₹385 Crore

Biodeal Pharmaceuticals, a Mumbai-based contract development and manufacturing organisation, has raised ₹385 crore from RMB Capitalworks, a unit of South African lender FirstRand Bank. This investment, announced on August 10, 2026, marks the first equity raise by the two-decade-old company.

The funds will be used for business expansion and research and development activities. Anurag Kumar, Chairman and Managing Director of Biodeal, stated that the company plans to expand into new segments and undertake research and development activities for new molecules.

RMB Capitalworks Managing Partner Anshuman Malur expressed that healthcare is a core focus for the platform, and Biodeal, with its passionate founders, fits the investment thesis of a differentiated player primed for rapid growth. As part of the deal, RMB Capitalworks will acquire an undisclosed stake in Biodeal.

In the financial year 2026, Biodeal reported revenue of ₹325 crore, with an operating profit margin of 20 per cent. The company aims to increase its revenue to ₹500 crore in FY27 and, with the help of new launches and expansion, reach ₹1,200 crore by FY30.

Biodeal's expansion plans and research and development activities are expected to drive growth in the company. The investment from RMB Capitalworks will provide the necessary funds to support these initiatives.

The pharmaceutical industry in India has been growing rapidly, driven by increasing demand for healthcare services and a rise in research and development activities. Biodeal's focus on contract development and manufacturing has positioned the company for growth in this sector.

With the investment from RMB Capitalworks, Biodeal is well-placed to achieve its revenue growth targets and expand its presence in the pharmaceutical industry. The company's plans for research and development activities will also contribute to the growth of the industry as a whole.

In conclusion, Biodeal Pharmaceuticals' raising of ₹385 crore from RMB Capitalworks is a significant development for the company and the pharmaceutical industry in India. The investment will support Biodeal's expansion plans and research and development activities, driving growth and positioning the company for success in the years to come.

The deal also highlights the growing interest of foreign investors in India's pharmaceutical sector, which is expected to continue growing in the coming years. As the demand for healthcare services increases, companies like Biodeal are well-placed to benefit from this trend.

Overall, the investment from RMB Capitalworks is a positive development for Biodeal Pharmaceuticals and the pharmaceutical industry in India. It will support the company's growth plans and contribute to the development of the industry as a whole.

The pharmaceutical sector is a significant contributor to India's economy, and the growth of companies like Biodeal will have a positive impact on the country's economic development. As the industry continues to grow, it is expected to create new job opportunities and drive innovation in the sector.

In the coming years, Biodeal Pharmaceuticals is expected to play a significant role in the growth of the pharmaceutical industry in India. With its focus on contract development and manufacturing, the company is well-placed to benefit from the growing demand for healthcare services and the increasing interest of foreign investors in the sector.

The company's plans for expansion and research and development activities will also contribute to the growth of the industry, driving innovation and creating new job opportunities. As the pharmaceutical sector continues to grow, it is expected to have a positive impact on India's economy and contribute to the country's economic development.

In conclusion, the raising of ₹385 crore by Biodeal Pharmaceuticals from RMB Capitalworks is a significant development for the company and the pharmaceutical industry in India. The investment will support the company's growth plans and contribute to the development of the industry as a whole, driving innovation and creating new job opportunities in the sector.